Phase III Trial of Docetaxel versus Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer
The PCCTC’s trial portfolio represents a substantial proportion of industry-sponsored and NIH-sponsored prostate cancer trials open in the US, characterizing a substantial presence in this research space. Our studies span the entire prostate cancer disease continuum and are strategically aligned with the Consortium’s own pathway-based scientific programs and a parallel commitment to the co-development of trial endpoints and biomarkers. Patient advocacy efforts are supported by Cancer ABCs.
Phase III Trial of Docetaxel versus Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer
An International Registry for Men with Advanced Prostate Cancer
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Principal Investigators Lorelei Mucci, ScD, MPH (Harvard T.H. Chan School of Public Health...
Learn MoreNew technology provides a major step forward in diagnosing and treating prostate cancer.
Learn MoreA new manuscript published in JCO Global Oncology describes the PCCTC managed IRONMAN Regi...
Learn MoreMore than 40,000 oncology professionals from around the world will convene at the annual A...
Learn MoreNORTH BILLERICA, MA, January 27, 2022 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus...
Learn MoreJoin our team of dedicated clinical research professionals! The Prostate Cancer Clinical Trials Consortium is currently seeking a Quality Manager and Clinical Data Manager to help fulfill our…
Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.